Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

fiercebiotech.com

FierceBiotech

Get the latest updates from FierceBiotech directly as they happen.

Follow now 337 followers

Latest posts

Last updated about 1 hour ago

Charles River debuts AI diagnostic tool to cut down pathology timelines

about 1 hour ago

Charles River is rolling out an artificial intelligence-backed digital pathology platform with...

Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model

about 2 hours ago

If any proof was needed that big money is still available for...

Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset

about 4 hours ago

Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure...

AstraZeneca’s $800M bet undermined by immunogenicity in phase 3

about 5 hours ago

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in...

Roche nabs European approval for second Eli Lilly-partnered Alzheimer’s test

about 7 hours ago

Roche has secured a European CE mark for its second Alzheimer’s test...

Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug

about 7 hours ago

Bayer has removed a protein therapeutic for hypertension and a treatment for...

Blood-based approach could detect early heart, kidney disease, study finds

about 9 hours ago

Scientists know that damage to microscopic blood vessels can provide an early...

Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled

about 10 hours ago

A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has...

Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed

about 12 hours ago

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying...

Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan

1 day ago

Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top...

Amid M&A rumor, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

1 day ago

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in...

Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech

1 day ago

Novo Nordisk has found the latest buyer for one of its orphaned...